TEXAS

Texas A&M University

Activated autologous T cell killing of CD 20+ B cell lymphoma in the Dog.

For further information on these trial contact: Heather Wilson, DVM, DACVIM (Oncology) 979-845-235 animalcancer@cvm.tamu.edu

Study details:

Species: Dogs

Tumor: Lymphoma

Purpose of Study: Any dog weighing over 35 lbs that has been diagnosed with B cell Lymphoma and is being treated with prednisone alone is eligible for this study.

Alteration of the intestinal microflora after chemotherapy in dogs.

Study details:

Species: Dogs

Tumor: Any cancer

Purpose of Study: dog must have a confirmed diagnosis of cancer and receive doxorubicin (a chemotherapy drug) as part of their treatment protocol. Two pretreatment fecal (stool) samples are needed and may be frozen before your first appointment.

We have also partnered with Sugarland Veterinary Specialists.

S100b inhibitors for the treatment of canine malignant melanoma

Study details:

Species: Dogs

Tumor: Melanoma

Purpose of Study: Inclusion Criteria and General Background Information: dog must have a confirmed diagnosis of melanoma and several tests to ensure his/her general health and to assess how advanced the disease is prior to treatment. The tumor will be biopsied prior to therapy. Tumors must be large enough to biopsy and your dog must have no other significant health problem. Your dog will receive one of two drugs or a combination of the two. Both drugs are FDA approved and have been used in dogs previously for other reasons. Interactions between these drugs and other drugs are unknown; therefore it is important to tell your veterinarian about any medications (and supplements) your dog is currently taking. It is strongly encouraged to eliminate all unnecessary medications. This should be discussed with your oncologist if you have any questions.

Radiation Therapy for dogs with multicentric lymphoma

For further information on this specific trial contact: Michael Deveau, MS, DVM, DAVR(Radiation Oncology) Clinic Phone: 979-845-2351, Email: animalcancer@cvm.tamu.edu

Study details:

Species: Dogs

Tumor: Lymphoma

Purpose of Study: Any dog weighing over 10 lbs that has been newly diagnosed with lymphoma. Dogs will receive full body imaging before therapy, then treated with chemotherapy for 19 weeks (stnadard therapy for canine lymphoma), after completion of chemotherapy dogs will receive 2 weeks (10 doses, M-F) of radiation therapy.

Evaluation of Iniparib in tumor-bearing dogs

Study details:

Species: Dogs

Tumor: melanoma, squamous cell carcinoma, soft tissue sarcoma or mammary carcinoma.

Purpose of Study: Any dog weighing over 21 lbs that has been diagnosed with melanoma, squamous cell carcinoma, soft tissue sarcoma or mammary carcinoma. Each dog will participate for 15-22 days in the study. There are two groups of dogs that will be enrolled. Group A will be dogs with any of the above tumor types and Group B is for dogs with mammary carcinoma only.

Evaluation of new renal (kidney) biomarkers for kidney damage in normal dogs and dogs receiving nephrotoxic drugs.

Study details:

Species: Dogs

Tumor: Kidney disease

Purpose of Study: Inclusion Criteria and General Background Information: Dogs receiving kidney toxic drugs (e.g., tyrosine kinase inhibitors): must be at least 2 years old, must weigh at least 22 lbs, must have no previous history of kidney disease or protein in the urine, must have a life expectancy of at least 4 months. Dogs receiving Kidney toxic drugs (e.g., tyrosine kinase inhibitors) will participate for up to 6 months with a pretreatment blood and urine sample, and additional samples two weeks after initiation of therapy and then monthly thereafter.